Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jan 8;9:165. doi: 10.3389/fnsys.2015.00165

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Mingote, Masson, Gellman, Thomsen, Lin, Merker, Gaisler-Salomon, Wang, Ernst, Hen and Rayport.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Genetic pharmacotherapy for glutaminase inhibition. The relative timing and magnitude of DNA, RNA, and behavioral effects are schematized prior to and after Tmx treatment. Black dotted line shows extrapolated DNA levels. Prior to Tmx, there was significant leaky recombination, but this did not impact GLS1 mRNA levels or behavior (amphetamine-induced locomotion). After Tmx, there was full recombination. At short and long-time points post-Tmx, both mRNA levels and amphetamine-induced hyperlocomotion showed the maximum effect at the short-time point. As in constitutive GLS1 Hets, amphetamine-induced hyperlocomotion was blocked at the short-time point, and strongly attenuated at the long-time point.